Cyclophosphamide
Mature T-cell and Nk-cell Neoplasms
National Cancer Institute (NCI)Small moleculePhase 1Active
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Mature T-cell and Nk-cell Neoplasms cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Bortezomib Swiss Cancer Institute | Phase 1 | CC |
Nelfinavir Swiss Cancer Institute | Phase 1 | CC |
Inno-206 Swiss Cancer Institute | Phase 1 | CC |
PREDNISONE TABLETS Swiss Cancer Institute | Phase 1 | CC |
DEXAMETHASONE Swiss Cancer Institute | Phase 1 | CC |
Same molecule, other indications
Cyclophosphamide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →